Galectin 3

• 

  Subject Areas on Research

  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. 
  • Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. 
  • Biomarker-based risk prediction in the community. 
  • Biomarkers for the Prevention of Heart Failure: Are We There Yet? 
  • Biomarkers in acute heart failure. 
  • Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Circulating galectin-3 in infections and non-infectious inflammatory diseases. 
  • Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. 
  • Effect of compressive force on unbinding specific protein-ligand complexes with force spectroscopy. 
  • Effect of high-intensity interval training on muscle remodeling in rheumatoid arthritis compared to prediabetes. 
  • Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. 
  • Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. 
  • Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. 
  • Galectin-3 directs antimicrobial guanylate binding proteins to vacuoles furnished with bacterial secretion systems. 
  • Galectin-3 expression in cardiac remodeling after myocardial infarction. 
  • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. 
  • Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). 
  • Galectin-3 in heart failure: more answers or more questions? 
  • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. 
  • Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. 
  • Guanylate Binding Proteins Regulate Inflammasome Activation in Response to Hyperinjected Yersinia Translocon Components. 
  • Importance of rigorous evaluation in comparative biomarker studies. 
  • Lack of galectin-1 or galectin-3 alters B cell deletion and anergy in an autoantibody transgene model. 
  • Letter by Januzzi regarding article, "galectin-3 and cardiac function in survivors of acute myocardial infarction". 
  • Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. 
  • Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. 
  • Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. 
  • Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. 
  • Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. 
  • Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. 
  • Soluble ST2 and galectin-3 in heart failure. 
  • State of the Art: Newer biomarkers in heart failure. 
  • Synephrine Hydrochloride Suppresses Esophageal Cancer Tumor Growth and Metastatic Potential through Inhibition of Galectin-3-AKT/ERK Signaling. 
  • Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. 
  • Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Distinguished Professor of Cardiology, Medicine, Clinical Pharmacology